PET/CT Localisation of a scapular haemangiopericytoma with tumour-induced osteomalacia

Singapore Medical Journal

Volumn 50, Issue 2, 2009, Pages

  Khadgawat, R ^a   Singh, Y ^a   Kansara, S ^a   Tandon, N ^a   Bal, C ^b   Seith, A ^b   Kotwal, P ^b  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b Department of Nuclear Medicine ^*

Author keywords

Mesenchymal tumours; Oncogenic osteomalacia; Paraneoplastic syndrome; Scapular haemangiopericytoma; Tumour induced osteomalacia

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; FLUORODEOXYGLUCOSE F 18; PARATHYROID HORMONE; PHOSPHATE; VITAMIN D;

ADULT; ARTICLE; BONE PAIN; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; FEMALE; FEMUR NECK; FOREARM; FOREARM FRACTURE; HEMANGIOPERICYTOMA; HUMAN; IRON DEFICIENCY ANEMIA; MUSCLE WEAKNESS; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENIC OSTEOMALACIA; OSTEOPENIA; OSTEOPOROSIS; POSITRON EMISSION TOMOGRAPHY; SCAPULAR HEMANGIOPERICYTOMA; SPINE; TUMOR LOCALIZATION;

ADULT; BONE DISEASES; CONTRAST MEDIA; FEMALE; FLUORODEOXYGLUCOSE F18; HEMANGIOPERICYTOMA; HUMANS; MAGNETIC RESONANCE IMAGING; OSTEOMALACIA; PARANEOPLASTIC SYNDROMES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SCAPULA; TOMOGRAPHY, X-RAY COMPUTED; VITAMIN D;

EID: 63449122155     PISSN: 00375675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Cai Q, Hodgson SF, Kao PC, et al. Brief report: inhibition of renal phosphate transport by a tumor product in a patient with oncogenic osteomalacia. N Engl J Med 1994; 330:1645-9.
2. Dupond JL, Mahammedi H, Prie D, et al. Oncogenic osteomalacia: diagnostic importance of fibroblast growth factor 23 and F-18 fluorodeoxyglucose PET/CT scan for the diagnosis and follow-up in one case. Bone 2005; 36:375-8.
3. Fukumoto S, Takeuchi Y, Nagano A, Fujita T. Diagnostic utility of magnetic resonance imaging skeletal survey in a patient with oncogenic osteomalacia. Bone 1999; 25:375-7.
4. Drezner MK. Tumour associated rickets and osteomalacia. In: Favus MJ, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 3rd ed. Philadelphia: Lippincott-Raven, 1996:319-25.
5. Takeuchi Y, Suzuki H, Ogura S, et al. Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia. J Clin Endocrinol Metab 2004; 89:3979-82.
6. Brame LA, White KE, Econs MJ. Renal phosphate wasting disorders: clinical features and pathogenesis. Semin Nephrol 2004; 24:39-47.
7. Hodgson SF, Clarke BL, Tebben PJ, et al. Oncogenic osteomalacia: localization of underlying peripheral mesenchymal tumors with use of Tc 99m sestamibi scintigraphy. Endocr Pract 2006; 12:35-42.
8. Jan de Beur SM, Streeten EA, Civelek AC, et al. Localisation of mesenchymal tumours by somatostatin receptor imaging. Lancet 2002; 359:761-3.
9. Kimizuka T, Ozaki Y, Sumi Y. Usefulness of 201Tl and 99mTc MIBI scintigraphy in a case of oncogenic osteomalacia. Ann Nucl Med 2004; 18:63-7.
10. Weidner N, Santa Cruz D. Phosphaturic mesenchymal tumors. A polymorphous group causing osteomalacia or rickets. Cancer 1987; 59:1442-54.
11. Roarke MC, Nguyen BD. PET/CT localization of phosphaturic mesenchymal neoplasm causing tumor-induced osteomalacia. Clin Nucl Med 2007; 32:300-1.
12. Hesse E, Moessinger E, Rosenthal H, et al. Oncogenic osteomalacia: exact tumor localization by co-registration of positron emission and computed tomography. J Bone Miner Res 2007; 22:158-62.